NASH - Nonalcoholic Steatohepatitis Clinical Trial
Official title:
A Phase I Single Dose Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.
Verified date | October 2021 |
Source | Sinew Pharma Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the safety, tolerability and Pharmacokinetic profile of SNP-630 when oral administered to healthy subjects.
Status | Completed |
Enrollment | 28 |
Est. completion date | August 31, 2021 |
Est. primary completion date | August 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 45 Years |
Eligibility | Inclusion Criteria: - A subject can participate in the study only if all the following criteria are met: 1. Between 20 and 45 years 2. Body weight 55 - 95 kg and body mass index (BMI) within the range 19 - 30 kg/m2 3. Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests, vital signs and 12-lead ECG. (A subject with a clinically insignificant abnormality or laboratory parameter(s) may be included only if the Investigator documents that the finding is unlikely to represent a safety risk and will not interfere with the study procedures.) 4. Male or Female of non-reproductive potential 5. Able to provide written informed consent, and understand and comply with the requirements of the study Exclusion Criteria: - Subjects who meet any of the following criteria are not eligible to enter the study: 1. History of any significant medical condition (e.g. Cardiovascular, pulmonary, metabolic, renal, gastrointestinal, urological, psychological disease, etc.) 2. With any surgical or medical condition possibly affecting drug absorption (e.g. cholecystectomy, gastrectomy, bowel disease, etc.), distribution, metabolism or excretion 3. History of liver disease, or known hepatic or biliary abnormalities 4. Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test (anti-HBc Ab) result at screening 5. AST, ALT, gamma-GT and total bilirubin >1.0x ULN 6. Creatinine >1.0 x ULN 7. Donation of blood or blood products in excess of 500 mL within 3 months 8. Has participated in a clinical trial and has received an investigational product within 3 months prior to dosing 9. Pregnant or lactating 10. Anticipated requirement for any prescription medication during the study. 11. History of sensitivity to any of the study medications, or components thereof or a history of anaphylaxis or severe allergy to drug or other substances 12. History or presence of alcohol abuse, defined as consumption of more than 210 mL of alcohol per week (the equivalent of 14 glasses of 120-mL wine or 14 cans of 350-mL beer), or other substance abuse within the prior two years |
Country | Name | City | State |
---|---|---|---|
Taiwan | Tri-Service General Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
Sinew Pharma Inc. |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): | An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. | 6 days | |
Secondary | Pharmacokinetic profile of SNP-630 | Concentrations of SNP-630 and it metabolites in plasma and urine will be measured by a specific and sensitive LC/MS/MS method developed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. According to the pharmacokinetic parameters of SNP-630 and its metabolites in health subjects oral SNP-630 to assess the safety information.The study will be conducted to validate the precision, accuracy (including with-run and between-run variation), linearity, specificity, reproducibility, limit of quantitation based on recovery studies. Assays will be performed in the laboratory of Clinical Pharmacokinetic Laboratory of Tri-Service General Hospital. Spiked samples of known concentrations will be analyzed together for quality control of the assay method. | 6 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03289897 -
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
|
N/A | |
Active, not recruiting |
NCT05479721 -
LITMUS Imaging Study
|
||
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Recruiting |
NCT04976283 -
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
|
Phase 4 | |
Completed |
NCT02784444 -
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
|
Phase 2 | |
Not yet recruiting |
NCT05499949 -
The Franciscus Obesity NASH Study
|
||
Completed |
NCT04321343 -
Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
Recruiting |
NCT04371042 -
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
|
||
Not yet recruiting |
NCT03648554 -
Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)
|
Phase 4 | |
Completed |
NCT04972396 -
ALT-801 DDI Study in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03748628 -
Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects
|
Phase 1 | |
Enrolling by invitation |
NCT05195944 -
Semaglutide vs Sitagliptin
|
Phase 4 | |
Completed |
NCT04643795 -
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
|
Phase 1 | |
Terminated |
NCT03669133 -
Vitamin E for NASH Treatment in HIV Infected Individuals
|
Phase 2 | |
Completed |
NCT04066400 -
Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis
|
N/A | |
Completed |
NCT03536650 -
Effect of DMR in the Treatment of NASH
|
N/A | |
Completed |
NCT03783897 -
A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
|
Phase 1 | |
Completed |
NCT04618744 -
A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
Active, not recruiting |
NCT05338034 -
Phase 2a Study of HPG1860 in Subjects With NASH
|
Phase 2 | |
Active, not recruiting |
NCT04653103 -
NASH in Subjects With Different Classes of Obesity
|